Clinical trials: Adenocarcinoma of Pancreas
Pancreatic Adenocarcinoma, Pancreatic Cancer Non-resectable
mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Modified FOLFIRINOX (mFOLFIRINOX) is the standard of care for patients with locally advanced pancreatic adenocarcinoma. While radiotherapy has been investigated for the management of resectable or locally advanced pancreatic…
- Trial name
- SABER (NCT04986930)
- Testing
- SBRT+mFOLFIRINOX, mFOLFIRINOX
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- Asan Medical Center
Locally Advanced Pancreatic Adenocarcinoma
Immunochemoradiotherapy in Patients With Pancreatic Cancer
This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger…
- Trial name
- NCT01342224
- Testing
- tadalafil and vaccination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Providence Health & Services
Pancreatic Adenocarcinoma Metastatic
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
The prognosis for pancreatic cancer remains dismal, with current guidelines favoring FOLFIRINOX or AG (consisting of Gemcitabine and Abraxane) as the primary chemotherapeutic option.
- Trial name
- NCT06396637
- Testing
- Sapropterin Dihydrochloride
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
RNA Precision Oncology in Advanced Pancreatic Cancer
The overall objective of this project is to determinate the feasibility of administering personalized therapy to subjects with advanced pancreatic cancer utilizing the novel OncoTreat platform.
- Trial name
- HIPPOCRATES (NCT04476537)
- Testing
- OncoTreat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Carcinoid Syndrome, Carcinoid
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to…
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- CAREFNDR (NCT07087054)
- Testing
- Paltusotine
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 141 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer
This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.
- Trial name
- NCT04631445
- Testing
- Ketogenic Diet
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Translational Drug Development
Pancreatic Cancer
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00885066
- Testing
- capecitabine, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Antoine Lacassagne
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04801095
- Testing
- WM-S1-030
- Where
- 6 sites in Australia, South Korea
- Volunteers
- 100 people
- Sponsor
- Wellmarker Bio
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma
In present study, the investigators evaluate the safety and efficacy of OIS-derived NASOX regimen (nal-IRI, S-1, oxaliplatin) in advanced pancreatic cancer.
- Trial name
- NASOX (NCT04662112)
- Testing
- NASOX
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Pancreatic Cancer
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00882765
- Testing
- genistein
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00474812
- Testing
- dasatinib, laboratory biomarker analysis, physiologic testing
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Endometrial Adenocarcinoma
PEN-866 in Patients With Advanced Solid Malignancies
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus
- Trial name
- NCT03221400
- Testing
- PEN-866 Sodium, fluorouracil, Folinic acid
- Where
- 16 sites in United States
- Volunteers
- 340 people
- Sponsor
- Tarveda Therapeutics
Von Hippel-Lindau Syndrome, Renal Cell Carcinoma
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
The goal of this clinical research study is to learn if sunitinib malate (SU011248) can help to control VHL. The safety of this drug will also be studied.
- Conditions
- Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
- Trial name
- NCT00330564
- Testing
- SU011248
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer of Pancreas, Cancer of the Pancreas
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
This is a phase II, multi-center, open-label, single-arm clinical trial to be conducted in the United States. In approximately 55 centers, approximately 75 eligible locally advanced unresectable or metastatic pancreatic cancer…
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
- Trial name
- APPRISE 1 (NCT00613730)
- Testing
- Gemcitabine, panitumumab
- Volunteers
- 3 people
- Sponsor
- Amgen
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
Pancreatic Neuroendocrine Tumors, Clear Cell Renal Carcinoma
Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project
The purpose of this study is to determine whether the use of Near-Infrared Technology can guide the laparoscopic resection of hypervascular neoplasms of the pancreas.
- Conditions
- Pancreatic Neuroendocrine Tumors, Clear Cell Renal Carcinoma, Solid Pseudopapillary Tumors of the Pancreas
- Trial name
- NCT02685553
- Testing
- NIR
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Universita di Verona
Advanced Solid Tumors, NSCLC Adenocarcinoma
A Study of MGC028 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined).
- Conditions
- Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
- Trial name
- NCT06723236
- Testing
- MGC028
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- MacroGenics
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Carcinoma, Pancreatic Ductal
Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. Around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in France and about 8.6% in Grand Est region.
- Trial name
- PESTIPAC (NCT04429490)
- Testing
- Adipose tissue sampling during surgery and urine sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- CHU de Reims
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.